Altered Extracellular Vesicle miRNA Profile in Prodromal Alzheimer’s Disease

Visconte, Caterina; Fenoglio, Chiara; Serpente, Maria; Muti, Paola; Sacconi, Andrea; Rigoni, Marta; Arighi, Andrea; Borracci, Vittoria; Arcaro, Marina; Arosio, Beatrice; Ferri, Evelyn; Golia, Maria Teresa; Scarpini, Elio; Galimberti, Daniela

doi:10.3390/ijms241914749

Cited by 10 publications

(8 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These novel results have demonstrated that plasma EVs show widespread deregulation of specific miRNAs, some of which are already known to be associated with neurological pathologies. A further validation analysis also confirmed significant upregulation of miR-16-5p, miR-25-3p, miR-92a-3p, and miR-451a in prodromal AD patients, suggesting these dysregulated miRNAs may be associated with the early onset of AD pathology [8].…”

mentioning

confidence: 67%

“…Among several markers, the nanosized extracellular vesicles (EVs), representing important mediators of cellular communication, are promising candidate biomarkers for neurodegenerative diseases like AD. Visconte et al [8] have isolated total EVs from the plasma of AD patients using ExoQuickULTRA exosome precipitation solution (SBI). Circulating total EVs were characterized using Nanosight nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and Western blotting.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Basic, Translational, and Clinical Research on Dementia

Bagetta,

Bano,

Scuteri

2024

IJMS

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 67%

mentioning

confidence: 99%

Basic, Translational, and Clinical Research on Dementia

Bagetta,

Bano,

Scuteri

2024

IJMS

View full text Add to dashboard Cite

show abstract

“…In AD, miRNAs in serum, cerebrospinal fluid, and brain tissue, as well as in transgenic models, have been studied [37][38][39][40][41]. Few studies have reported miRNAs in the early stages or related to the progression of AD [22,[41][42][43][44][45][46]. Nevertheless, the specific alterations in the transcriptome of mesenchymal stem cells (MSCs) obtained from individuals with familial Alzheimer's disease (FAD) are not yet understood at various stages of the condition.…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal Stem Cells from Familial Alzheimer’s Patients Express MicroRNA Differently

Rochín-Hernández,

Padilla-Cristerna

et al. 2024

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the predominant form of dementia globally. No reliable diagnostic, predictive techniques, or curative interventions are available. MicroRNAs (miRNAs) are vital to controlling gene expression, making them valuable biomarkers for diagnosis and prognosis. This study examines the transcriptome of olfactory ecto-mesenchymal stem cells (MSCs) derived from individuals with the PSEN1(A431E) mutation (Jalisco mutation). The aim is to determine whether this mutation affects the transcriptome and expression profile of miRNAs and their target genes at different stages of asymptomatic, presymptomatic, and symptomatic conditions. Expression microarrays compare the MSCs from mutation carriers with those from healthy donors. The results indicate a distinct variation in the expression of miRNAs and mRNAs among different symptomatologic groups and between individuals with the mutation. Using bioinformatics tools allows us to identify target genes for miRNAs, which in turn affect various biological processes and pathways. These include the cell cycle, senescence, transcription, and pathways involved in regulating the pluripotency of stem cells. These processes are closely linked to inter- and intracellular communication, vital for cellular functioning. These findings can enhance our comprehension and monitoring of the disease’s physiological processes, identify new disorder indicators, and develop innovative treatments and diagnostic tools for preventing or treating AD.

show abstract

“…A study by Visconte et al [ 85 ] also demonstrated the potential usefulness of miRNAs derived from plasma exosomes. The study used extracted miRNAs from 11 patients with AD, 20 control patients, and 19 patients with mild cognitive impairment without AD.…”

Section: Application Of Micrornas As Biomarkers For Alzheimer’s Disea...mentioning

confidence: 98%

Potential Application of MicroRNAs and Some Other Molecular Biomarkers in Alzheimer’s Disease

Paprzycka,

Wieczorek,

Nowak

et al. 2024

CIMB

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the world’s most common neurodegenerative disease, expected to affect up to one-third of the elderly population in the near future. Among the major challenges in combating AD are the inability to reverse the damage caused by the disease, expensive diagnostic tools, and the lack of specific markers for the early detection of AD. This paper highlights promising research directions for molecular markers in AD diagnosis, including the diagnostic potential of microRNAs. The latest molecular methods for diagnosing AD are discussed, with particular emphasis on diagnostic techniques prior to the appearance of full AD symptoms and markers detectable in human body fluids. A collection of recent studies demonstrates the promising potential of molecular methods in AD diagnosis, using miRNAs as biomarkers. Up- or downregulation in neurodegenerative diseases may not only provide a new diagnostic tool but also serve as a marker for differentiating neurodegenerative diseases. However, further research in this direction is needed.

show abstract

Altered Extracellular Vesicle miRNA Profile in Prodromal Alzheimer’s Disease

Cited by 10 publications

References 71 publications

Basic, Translational, and Clinical Research on Dementia

Basic, Translational, and Clinical Research on Dementia

Mesenchymal Stem Cells from Familial Alzheimer’s Patients Express MicroRNA Differently

Potential Application of MicroRNAs and Some Other Molecular Biomarkers in Alzheimer’s Disease

Contact Info

Product

Resources

About